BERLIN (EGMN) - The oral, multitargeted agent sorafenib has demonstrated activity in breast cancer for the first time.Adding sorafenib (Nexavar) to capecitabine (Xeloda) significantly improved the time to disease progression in locally advanced or metastatic breast cancer in the placebo-controlled phase IIB SOLTI-0701 trial presented as a late-breaking abstract at the joint Congress of the European Cancer Organization (ECCO) and the European Society for Medical Oncology (ESMO)."After Avastin [bevacizumab],...